View in EDS

Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.

Saved in:
Bibliographic Details
Title: Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.
Authors: Aredo JV; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Wakelee HA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Ramchandran KJ; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Neal JW; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Diehn M; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Hui AB; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Salahudeen A; Department of Internal Medicine, University of Illinois Cancer Center, Chicago, Illinois., Kwong B; Department of Dermatology, Stanford University School of Medicine, Stanford, California., Berry GJ; Department of Pathology, Stanford University School of Medicine, Stanford, California., Guo HH; Department of Radiology, Stanford University School of Medicine, Stanford, California., Cunanan K; Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California., Vali S; Cellworks Group, South San Francisco, California (Prior)., Pancirer D; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Tsang V; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Hwang G; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Loza M; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Johnson B; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Blanchard I; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Padda SK; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Hematology/Oncology, Fox Chase Cancer Center/Temple Health, Philadelphia, Pennsylvania.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2024 Oct 17; Vol. 5 (12), pp. 100741. Date of Electronic Publication: 2024 Oct 17 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39624248
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Aredo+JV%22">Aredo JV</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Wakelee+HA%22">Wakelee HA</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Ramchandran+KJ%22">Ramchandran KJ</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Neal+JW%22">Neal JW</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Diehn+M%22">Diehn M</searchLink>; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Hui+AB%22">Hui AB</searchLink>; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Salahudeen+A%22">Salahudeen A</searchLink>; Department of Internal Medicine, University of Illinois Cancer Center, Chicago, Illinois.<br /><searchLink fieldCode="AU" term="%22Kwong+B%22">Kwong B</searchLink>; Department of Dermatology, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Berry+GJ%22">Berry GJ</searchLink>; Department of Pathology, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Guo+HH%22">Guo HH</searchLink>; Department of Radiology, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Cunanan+K%22">Cunanan K</searchLink>; Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Vali+S%22">Vali S</searchLink>; Cellworks Group, South San Francisco, California (Prior).<br /><searchLink fieldCode="AU" term="%22Pancirer+D%22">Pancirer D</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Tsang+V%22">Tsang V</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Hwang+G%22">Hwang G</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Loza+M%22">Loza M</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Johnson+B%22">Johnson B</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Blanchard+I%22">Blanchard I</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.<br /><searchLink fieldCode="AU" term="%22Padda+SK%22">Padda SK</searchLink>; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.; Department of Hematology/Oncology, Fox Chase Cancer Center/Temple Health, Philadelphia, Pennsylvania.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101769967%22">JTO clinical and research reports</searchLink> [JTO Clin Res Rep] 2024 Oct 17; Vol. 5 (12), pp. 100741. <i>Date of Electronic Publication: </i>2024 Oct 17 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101769967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3643 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663643%22">26663643 </searchLink><i>NLM ISO Abbreviation: </i>JTO Clin Res Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39624248
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtocrr.2024.100741
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100741
    Titles:
      – TitleFull: Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Aredo JV
      – PersonEntity:
          Name:
            NameFull: Wakelee HA
      – PersonEntity:
          Name:
            NameFull: Ramchandran KJ
      – PersonEntity:
          Name:
            NameFull: Neal JW
      – PersonEntity:
          Name:
            NameFull: Diehn M
      – PersonEntity:
          Name:
            NameFull: Hui AB
      – PersonEntity:
          Name:
            NameFull: Salahudeen A
      – PersonEntity:
          Name:
            NameFull: Kwong B
      – PersonEntity:
          Name:
            NameFull: Berry GJ
      – PersonEntity:
          Name:
            NameFull: Guo HH
      – PersonEntity:
          Name:
            NameFull: Cunanan K
      – PersonEntity:
          Name:
            NameFull: Vali S
      – PersonEntity:
          Name:
            NameFull: Pancirer D
      – PersonEntity:
          Name:
            NameFull: Tsang V
      – PersonEntity:
          Name:
            NameFull: Hwang G
      – PersonEntity:
          Name:
            NameFull: Loza M
      – PersonEntity:
          Name:
            NameFull: Johnson B
      – PersonEntity:
          Name:
            NameFull: Blanchard I
      – PersonEntity:
          Name:
            NameFull: Padda SK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 10
              Text: 2024 Oct 17
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3643
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: JTO clinical and research reports
              Type: main
ResultId 1